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4. South African society still has archaic and paternalistic 
patterns. The legal system appears to be failing the victims of 
sexual abuse. Adults must take responsibility for not using 
children and adolescents to satisfy their own needs. 
5. Sexual crimes are endemic in South Africa and it is not 
uncommon for women to have experienced multiple rapes 
before they reach adulthood. Have we become so desensitised 
that even in the legal proceedings sexual abuse is accepted as 
the norm?
We urge government to finalise the New Sexual Offences 
Bill. It redefines rape to include male victims and penetration 
of body orifices with non-sexual organs. It also sets the age 
of consent for all forms of sexual activity at 16 years for boys 
and girls. Children under the age of 12 are confirmed to be 
incapable of consenting to sex, but the Bill includes a qualified 
decriminalisation of sexual experimentation where this 
occurs between children aged 12 - 15 years, provided that the 
difference in age is not more than 2 years.
It is widely acknowledged that a ‘cycle of abuse’ exists. A 
main factor in becoming a child sexual perpetrator is having 
been sexually abused as a child. Therefore the apparent increase 
in number of sexual assaults on children is of even greater 
concern, as this is likely to drive a cycle of ever-increasing 
abuse.
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The South African Hypertension 
Guideline 2006 is evidence-based and 
not cost-effective – a rebuttal
To the Editor: Gaziano1 criticises the South African 
Hypertension (SAH) Guideline 20062 for being evidence-based 
but not cost-effective. He argues that global cardiovascular 
(CVS) risk assessment is important in making informative 
cost-effective treatment decisions. He gives examples that cost 
of treatment may range from US$20 000 per life-year saved to 
US$2 000 000, depending on the underlying global CVS risk. He 
argues that the SAH Guideline is too imprecise to assess CVS 
risk, and that patients at high risk may be denied treatment 
and patients at low risk may be treated inappropriately. For 
example, Gaziano argues that a patient with blood pressure 
(BP) below 140/90 mmHg may have an absolute risk between 
1% and 25%, which is too large to make effective decisions. 
Additionally, a significant amount of information can be lost 
by creating a change from one risk category to the next by 
the presence of 1 - 2 major risk factors, many of which are 
dichoctomised. 
It is very unfortunate that the SAMJ did not give the SAH 
Guideline Committee the opportunity to respond to Gaziano’s 
criticism in the same issue of the journal. The Committee gave 
considerable thought to both cost-effective and evidence-based 
guidelines. There was complete agreement that a CVS risk-
assessment strategy should be adopted to optimise resources 
to patients at higher risk. However, there was considerable 
debate with regard to whether the Committee should adopt 
the global CVS risk assessment or an absolute risk assessment. 
It was decided to base our policy on the absolute risk table 
of the ESH/ESC guidelines,3 mainly for practical reasons of 
implementation in the primary care setting. Gaziano himself 
states that ‘Guidelines must focus on the absolute or global 
clinical risk instead of the individual risk factors approaches in order 
to achieve an overall cost-effective reduction of disease.’1
Gaziano is indeed correct that the actual absolute risks 
are not stated in the Guideline, and this is an omission. Low, 
medium, high and very high risk give an absolute risk of CVS 
event in the next 10 years of < 15%, 15 - 20%, 20 - 30% and > 
30% based on Framingham data, and absolute risk of CVS 
death of < 4%, 4 - 5%, 5 - 8%, and > 8% based on the SCORE 
charts respectively.3 
Gaziano suggests that a 45-year-old male with no risk factors 
has a 2% chance of developing a CVS event in the next 10 
years and will ultimately require therapy according to the SAH 
Guideline, whereas a 55-year-old smoker with a low-density 
lipoprotein/high-density lipoprotein (LDL/HDL) cholesterol 
ratio of 6, and BP 139/84 mmHg, would not be treated 
according to the Guideline because he is at low risk, whereas 
his actual risk is 25% in the next 10 years. Let us examine these 
examples more carefully.
The first patient is clearly at low CVS risk, and there is 
agreement between Gaziano and the SAH risk table. The SAH 
Guideline recommends that the patient undergo lifestyle 
changes for the next 6 - 12 months and then requires drug 
treatment if the BP level remains above 140/90 mmHg. Gaziano 
is at issue with this policy as it is not cost-effective. It is purely 
speculative whether this patient will indeed require drug 
treatment. Most clinicians recognise that this patient is most 
likely to have white-coat hypertension because of the lack of 
risk factors and target organ damage. Repeated monitoring, 
which results in habituation to BP measurement, or self- or 
ambulatory BP monitoring, may reveal a quite normal BP 
profile in time. Additionally, lifestyle changes may also be 
helpful. Furthermore, if BP is still not controlled after 12 
months, this patient is likely to be treated with a low-dose 
thiazide plus angiotensin-converting enzyme (ACE) inhibitor. 
The current cost in the state sector is R3.33 per month. Based 
on the risk table published by Gaziano,1 the number needed to 
treat for 10 years to prevent 1 event is 33 and the direct drug 
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costs to the state sector will be R1 368. According to the Gaziano 
risk chart the patient must remain untreated for 10 years even 
if his BP remains persistently elevated at levels just below 
180/110 mmHg, and this approach takes no cognisance of the 
patient’s high lifetime risk for a CVS event. 
With regard to the second case, Gaziano states that according 
to the SAH Guideline the patient will not be treated as he is at 
low risk. This is simply not true. The Guideline explicitly states 
that this patient must undergo lifestyle changes (cessation of 
smoking, dietary change and exercise), which will dramatically 
lower his risk. More importantly, however, Gaziano exploits a 
weakness in any risk table by creating an artificial patient with 
major risk factors just below the dichotomised thresholds. If we 
merely change the patient’s age to 55 years and 1 month, he has 
3 major risk factors and therefore is at high CVS risk. This type 
of anomaly can be just as easily exploited in the risk chart creat-
ed by Gaziano because of dichotomisation of age. For instance, 
a 54-year-old man with a total cholesterol 6.9 mmol/l and BP 
179/109 mmHg with no other risk factors, and a 53-year-old 
diabetic with total cholesterol 4.9 mmol/l and BP 169/109 
mmHg, have the same CVS risk as a 35-year-old male with BP 
130/80 mmHg and total cholesterol 4.1 mmol/l, namely less 
than 20%, and both patients require no drug treatment.  How-
ever, it must be explicitly stated that these arguments are not 
directed at belittling the global risk chart created by Gaziano, 
but the use of his chart in the South African context needs to 
be debated. It must always be emphasised that every guideline 
or risk chart (table) has its potential weaknesses or anomalies 
that can be exploited by creating imaginary patients. These risk 
charts are guidelines only and must be used in conjunction with 
good clinical judgement, assessment of target organ damage 
and recognition of associated conditions.  
Finally, we would like to state categorically that the SAH 
Guideline in no way intends to diminish the need for lifestyle 
intervention as implied by Gaziano. It is quite clear from 
the whole tone of the guideline that lifestyle intervention 
is critically important and is the first step in the treatment 
algorithm regardless of CVS risk. 
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Salmonella typhi central nervous system 
infection
To the Editor:  This report aims to document Salmonella typhi as 
a cause of central nervous system infection.
Typhoid fever is caused by the facultative intracellular 
organisms S. enterica serotype Typhi (S. typhi) and S. paratyphi.1 
Infection is mainly associated with ingestion of contaminated 
water and food.1 One to five per cent of people become chronic 
carriers despite antibiotic treatment,1 while co-infection with 
Schistosoma spp. may contribute to this condition.2 With an 
incubation period ranging from 5 to 21 days,1 characteristic 
symptoms may include headache, fever, gastrointestinal 
disturbances, relative bradycardia, splenomegaly and 
leucopenia.1 Extra-intestinal infectious complications involving 
various systems may occur.1  
A 47-year-old man presented with generalised weakness 
and paralysis, including a spell of general seizures.  Clinical 
examination revealed a Glasgow Coma Scale of 5/15, rigidity, 
increased tone, papilloedema and neck stiffness.  Lateralising 
signs were present. 
A cerebrospinal fluid (CSF) sample was collected 
and processed.  CSF microscopic analysis revealed 35 
polymorphonuclear cells/μl, 7 lymphocytes/μl and 188 
erythrocytes/μl. Gram-negative bacteria were observed on 
Gram stain, while capsular antigen detection was negative. 
Serum C-reactive protein level was 194.5 mg/l and full blood 
count revealed a leukocyte count of 6.20 x 109 cells/l. Computed 
tomography (CT) revealed communicating hydrocephalus.  
Non-lactose fermenting colonies were observed on 
MacConkey agar within 24 hours (Oxoid, England). 
Biochemical identification (API 20E, Biomerieux SA, Marcy-
l’Etoile, France) revealed S. typhi.  Trace amounts of hydrogen 
sulphide, positive Vi antigen agglutination (Wellcolex, Remmel) 
and the general biochemical inert nature, confirmed the 
identification.3 The isolate tested sensitive to all antibiotics 
analysed (enterobacteriaceae panel, Clinical Laboratory 
Standards Institute).4-6 
Intravenous cefotaxime (2 g q4h) was commenced at 
admission.  However, the patient died 2 days later. 
Central nervous system (CNS) infection with S. typhi occurs 
in 3 - 35% of patients. A wide range of CNS manifestations 
include encephalopathy, meningitis, transient parkinsonism, 
motor neuron disorders, ataxia, cerebral abscesses, cerebral 
oedema, seizures, and Guillain-Barré syndrome.1 Patients 
present with fever, headache, vomiting, seizures, altered 
state of consciousness, papilloedema and focal neurological 
deficits.1 Neuro-imaging may be helpful when a lumbar 
puncture is contraindicated.1 In this case microbiological 
examination of the CSF established the diagnosis of S. typhi 
infection.  Parenteral ceftriaxone for 14 - 28 days is the 
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recommended therapy.1 Corticosteroids are recommended 
as adjunctive therapy for children with S. typhi meningitis, 
although this is still controversial in adults.1 A review from 1884 
to 1984 documented eight cases of focal intracranial lesions 
caused by S. typhi.1,7 Bacteraemia  with S. typhi may involve 
multiple systems; however serious extra-intestinal infectious 
complications are relatively uncommon.
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SAMA URGES DOCTORS TO IMPROVE SKILLS FOR EFFECTIVE MANAGEMENT OF TUBERCULOSIS
The growing incidence of extreme drug-resistant tuberculosis in South Africa highlights the urgent need for more doctors to 
diagnose, prevent, detect and manage TB effectively. Currently South Africa ranks seventh in reported TB cases in the world, 
and is among the 22 high-burden countries targeted as part of the World Health Organization’s Stop TB initiative. In 2002, 
the incidence rate in South Africa was just under 300/100 000 population.
The South African Medical Association (SAMA) recognises the threat that TB poses to the South African population. SAMA, 
in conjunction with the Foundation for Professional Development (FPD), has embarked on a project that offers doctors 
countrywide the opportunity to enrol for a course in the management of tuberculosis. The training course is specifically 
targeted at doctors in the private sector with a view to complementing the efforts and activities around TB in the public 
health sector. 
‘We must pool our skills and resources to deal with the burden of TB and the effect the disease has on the quality of life 
and the productivity of our population. SAMA encourages every doctor to enrol for this course,’ said Dr Aquina Thulare, 
Secretary-General of SAMA. 
A considerable international grant from PEPFAR has made it possible for the FPD to offer this training programme at only 
R228 per person. Without sponsorship, this course would have cost approximately R2 200. 
The course is aimed at providing doctors with the appropriate skills to:
• Diagnose, prevent, detect and manage TB
• Treat tuberculosis
•  Prevent long-term complications with the 
reduction of premature morbidity and 
mortality
• Promote education and self-care
• Control associated disorders
• Promote therapy compliance
• Improve quality of life and productivity
• Reduce the economic burden on the 
individual, family and community.
The training course, which comprises self-
study modules and a 2-day interactive 
workshop, will be accredited according to 
the CPD guidelines of the Health Professions 
Council of South Africa published in 
November 2006. 
The first workshop is scheduled for March 10 and 11 in Midrand. For more information and registration, contact Pepe Mchiza 
or Zandi Pule on 012 481-2089/2101 or enquire at pepem@foundation.co.za / zandip@foundation.co.za  
Dates and venues of workshops for the Management of Tuberculosis
Venue Date
Midrand March 10 and 11
Cape Town March 17 and 18
Kimberley April 14 and 15
Port Elizabeth April 21 and 22
Durban May 5 and 6
Polokwane May 19 and 20
Nelspruit May 26 and 27
Bloemfontein June 2 and 3
Klerksdorp June 9 and 10
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